Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations and k-ras oncogene mutations in patients with stage III non-small cell lung cancer.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106|
- Overall survival [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
- Progression free survival [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||November 2005|
|Study Completion Date:||July 2010|
|Primary Completion Date:||March 2006 (Final data collection date for primary outcome measure)|
Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
|Genetic: molecular diagnostic method Genetic: mutation analysis|
- Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106.
- Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response to treatment in these patients.
OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras mutations.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898924
|Study Chair:||Pasi Janne, MD, PhD||Dana-Farber Cancer Institute|